Board Certified Gynecologic Oncologist
|Mailing Address:||Division of Gynecologic Oncology
Dept of Ob/Gyn & Reproductive Sciences
490 Illinois Street, Floor 10, Box 0132
San Francisco, CA 94143
Dr. Yvonne G. Lin-Liu specializes in treating gynecologic cancers. She believes that knowledge is power, so she strives to help her patients understand the biology of their disease and all of their treatment options. Much of her practice focuses on serving women seeking second opinions and helping them make the best treatment decisions.
After earning a bachelor's degree in chemistry from the Massachusetts Institute of Technology, Lin-Liu completed a master of science degree in epidemiology at the Harvard T.H. Chan School of Public Health and then received a Fulbright fellowship to Taiwan. She earned her medical degree from the University of California, Irvine. She completed a residency in obstetrics and gynecology at Beth Israel Deaconess Medical Center and a fellowship in gynecologic oncology at the University of Texas MD Anderson Cancer Center.
Previously, Lin-Liu was an NCI-funded physician-scientist studying the impact of obesity on cellular stress, inflammation and endometrial cancer development. She joined Genentech in 2014 to advance the development of new cancer therapies for women around the world. Currently a Group Medical Director at Genentech, she strongly believes that continuing to care for patients as a physician is key to improving treatment options for women with gynecologic cancers.
Lin-Liu has presented her research at multiple meetings and has published in prominent journals. She is a member the Society of Gynecologic Oncology, Western Association of Gynecologic Oncologists, American Association for Cancer Research and American Society of Clinical Oncology. She volunteers on various society committees focused on professional development and serves on the editorial board of various journals.
|Year||Institution & Location||Degree||Field of Study|
|1993||Massachusetts Institute of Technology, Cambridge, MA,||SB||Chemistry|
|1995||Harvard School of Public Health, Boston, MA,||MS||Epidemiology|
|2001||University of California-Irvine College of Medicine, Irvine, CA||MD||Medicine|
|2005||Beth Israel Deaconess Medical Center, Boston,MA||Residency||Obstetrics & Gynecology|
|2009||The University of Texas M.D. Anderson Cancer Center, Houston, Texas||Fellowship||Gynecologic Oncology|
Achievements & Recognition
|2013||NIH/NCI Career Development Award|
|2011||Gynecologic Cancer Foundation/St. Louis Ovarian Cancer Awareness Research Award|
1. Lin YG, Shen J, Yoo E, Liu R, Yen HY, Mehta A, Rajaei A, Yang W, Mhawech-Fauceglia P, DeMayo FJ,Lydon J, Gill P, Lee AS: Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis. Oncogene [Epub ahead of print] 2015. [PMID:25684138.]
2. Wu E, Rogers A, Ji L, Sposto R, Church T, Roman L, Tripathy D, Lin YG: Escalation of oncologic services at the end of life among patients with gynecologic cancer at an urban, public hospital. J Oncol Pract. [Epub ahead of print], 2015. [PMID:25604595]
3. Gray MJ, Mhawech-Fauceglia P, Yoo E, Yang W, Wu E, Lee AS, Lin YG: AKT inhibition mitigates GRP78 (Glucose-regulated Protein) expression and contribution to chemoresistance in endometrial cancers. Int J Cancer, 133(1): 21-30, 2013. [PMID:23280503]
4. Matsuo K, Gray MJ, Yang DY, Srivastava SA, Tripathi PB, Sonoda LA, Yoo EJ, Dubeau L, Lee AS, Lin YG:The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival. Gynecol Oncol 128:552-9, 2013.[PMID:23200913]
5. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ,Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK: Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359:2641-50, 2008. [PMID:19092150]
6. Lin YG, Immaneni A, Merritt WM, Mangala SL, Kim S, Shahzad M, Tsang Y, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka D, Brinkley W, Sood AK: Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14: 5437-46, 2008. [PMID:18765535]
7. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK: Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. JNCI 100:359-72, 2008. [PMID:18314475]
8. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK: Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67:10976-83, 2007. [PMID:18006843]
9. Landen CN, Lin YG, Armaiz-Pena GN, Das PD, Arrevalo JM, Kamat AA, Han LY, Jennings NB, Spannuth WA, Thaker PH, Lutgendorf SK, Savary CA, Sanguino AM, Lopez-Berenstein G, Cole SW, Sood AK: Neuroendocrine modulation of STAT3 in ovarian cancer. Cancer Res 67:10389-96, 2007.[PMID:17974982]
10. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings,NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK: Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13:4209-17, 2007. [PMID:17634550]
11. Landen CN, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA, Bodurka DC, Gershenson DM, Brinkley WR, Sood AK: Overexpression of centrosomal protein Aurora A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13:4098-104, 2007. [PMID:17634535]
12. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Lutgendorf SK, Aggarwal BB, Sood AK: Curcumin inhibits tumor growth and angiogenesis in ovariacarcinoma by targeting the nuclear factor-κB pathway. Clin Cancer Res 13:3423-3430, 2007.[PMID:17545551]
13. Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS,Sood AK: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109:332-40,2007. [PMID:17154180]
14. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Med 12:939-44, 2006. [PMID:16862152]